急性缺血性卒中血管内治疗后非梗死组织中的对比剂染色
该回顾性研究纳入194例前循环大血管闭塞急性缺血性卒中血管内治疗患者,非梗死组织对比剂染色发生率为13.4%(26/194),平均CT衰减值40 HU,低于梗死组织染色的53 HU;非梗死组织染色患者住院期间无临床恶化,出院mRS中位数3 vs 4(P = .018),未发现独立预测因素。
要点
- 非梗死组织对比剂染色发生率为13.4%(26/194),平均CT衰减值40 HU,低于梗死组织染色的53 HU。
- 非梗死组织染色患者住院期间无临床恶化,出院mRS中位数3 vs 4(P = .018)。
- 非梗死组织染色可模仿梗死组织和脑水肿,认识其特征对避免误判很重要。
核心结论
- 急性缺血性卒中血管内治疗后对比剂染色可出现在梗死组织之外,可能归因于缺血但未梗死组织中血脑屏障的可逆性破坏;该现象通常良性,但识别其特征很重要,因其可能模仿梗死组织和脑水肿等病理状况。
研究设计与样本
- 回顾性研究,纳入连续接受血管内治疗的前循环大血管闭塞急性缺血性卒中患者194例;对比剂染色定义为血管内治疗后CT上新出现的高密度,根据随访MR弥散加权成像是否存在弥散受限分为梗死组织对比剂染色和非梗死组织对比剂染色。
关键影像表现/征象
- 非梗死组织对比剂染色区域平均CT衰减值为40 HU,显著低于梗死组织对比剂染色区域的53 HU。
- 非梗死组织对比剂染色在CT上表现为新出现的高密度,随访MR弥散加权成像无弥散受限。
诊断标准与关键数值
- 对比剂染色定义为血管内治疗后CT上新出现的高密度。
- 梗死组织对比剂染色:染色区域在随访MR弥散加权成像上显示弥散受限。
- 非梗死组织对比剂染色:染色区域在随访MR弥散加权成像上无弥散受限。
临床应用与阅片要点
- 非梗死组织对比剂染色通常良性,但可模仿梗死组织和脑水肿,阅片时需结合随访MR弥散加权成像鉴别;非梗死组织染色患者更可能具有ASPECTS 8-10、与梗死组织染色相关且实现成功再灌注。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Contrast staining is a common finding after endovascular treatment of acute ischemic stroke. It typically occurs in infarcted tissue and is considered an indicator of irreversible brain damage. Contrast staining in noninfarcted tissue has not been systematically investigated. We sought to assess the incidence, risk factors, and clinical significance of contrast staining in noninfarcted tissue after endovascular treatment.
MATERIALS AND METHODS: We conducted a retrospective review of consecutive patients who underwent endovascular treatment for anterior circulation large-vessel occlusion acute ischemic stroke. Contrast staining, defined as new hyperdensity on CT after endovascular treatment, was categorized as either contrast staining in infarcted tissue if the stained region demonstrated restricted diffusion on follow-up MR imaging or contrast staining in noninfarcted tissue if the stained region demonstrated no restricted diffusion. Baseline differences between patients with and without contrast staining in noninfarcted tissue were compared. Logistic regression was used to identify independent associations for contrast staining in noninfarcted tissue after endovascular treatment.
RESULTS: Among 194 patients who underwent endovascular treatment for large-vessel occlusion acute ischemic stroke and met the inclusion criteria, contrast staining in infarcted tissue was noted in 52/194 (26.8%) patients; contrast staining in noninfarcted tissue, in 26 (13.4%) patients. Both contrast staining in infarcted tissue and contrast staining in noninfarcted tissue were noted in 5.6% (11/194). Patients with contrast staining in noninfarcted tissue were found to have a higher likelihood of having an ASPECTS of 8-10, to be associated with contrast staining in infarcted tissue, and to achieve successful reperfusion compared with those without contrast staining in noninfarcted tissue. In contrast staining in noninfarcted tissue regions, the average attenuation was 40 HU, significantly lower than the contrast staining in infarcted tissue regions (53 HU). None of the patients with contrast staining in noninfarcted tissue had clinical worsening during their hospital stay. The median discharge mRS was significantly lower in patients with contrast staining in noninfarcted tissue than in those without (3 versus 4; P = .018). No independent predictors of contrast staining in noninfarcted tissue were found.
CONCLUSIONS: Contrast staining can be seen outside the infarcted tissue after endovascular treatment of acute ischemic stroke, likely attributable to the reversible disruption of the BBB in ischemic but not infarcted tissue. While generally benign, understanding its characteristics is important because it may mimic pathologic conditions such as infarcted tissue and cerebral edema.
引用
- Abdalkader M, Nguyen TN, Sahoo A, et al. Contrast Staining in Noninfarcted Tissue after Endovascular Treatment of Acute Ischemic Stroke. AJNR Am J Neuroradiol. 2024. PMID: 38697792. doi:10.3174/ajnr.A8222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。